This image shows Arnulf Stenzl

Prof. Dr. med. Dr. h.c.

Arnulf Stenzl

University Hospital Tübingen
Department of Urology
[Photo: Klinik für Urologie]

Contact

+49 7071 29 86613
+49 7071 29 5092

Business card (VCF)

Hoppe-Seyler-Str. 3
72076 Tübingen
Germany

Items 1-200 of 200 (Display the 200 citations in PubMed)

1.

ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer.

Armstrong AJ, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Azad A, Alcaraz A, Alekseev B, Iguchi T, Shore ND, Rosbrook B, Sugg J, Baron B, Chen L, Stenzl A.

J Clin Oncol. 2019 Nov 10;37(32):2974-2986. doi: 10.1200/JCO.19.00799. Epub 2019 Jul 22.

PMID: 31329516Free PMC article.Clinical Trial.

2.

Trimodal therapy for muscle-invasive bladder cancer.

Mathes J, Rausch S, Todenhöfer T, Stenzl A.

Expert Rev Anticancer Ther. 2018 Dec;18(12):1219-1229. doi: 10.1080/14737140.2018.1535314. Epub 2018 Oct 17.

PMID: 30324833Review.

3.

Urinary diversion after radical cystectomy for bladder cancer: options, patient selection, and outcomes.

Lee RK, Abol-Enein H, Artibani W, Bochner B, Dalbagni G, Daneshmand S, Fradet Y, Hautmann RE, Lee CT, Lerner SP, Pycha A, Sievert KD, Stenzl A, Thalmann G, Shariat SF.

BJU Int. 2014 Jan;113(1):11-23. doi: 10.1111/bju.12121.

PMID: 24330062Review.

4.

Prevention and early detection of prostate cancer.

Cuzick J, Thorat MA, Andriole G, Brawley OW, Brown PH, Culig Z, Eeles RA, Ford LG, Hamdy FC, Holmberg L, Ilic D, Key TJ, La Vecchia C, Lilja H, Marberger M, Meyskens FL, Minasian LM, Parker C, Parnes HL, Perner S, Rittenhouse H, Schalken J, Schmid HP, Schmitz-Dräger BJ, Schröder FH, Stenzl A, Tombal B, Wilt TJ, Wolk A.

Lancet Oncol. 2014 Oct;15(11):e484-92. doi: 10.1016/S1470-2045(14)70211-6.

PMID: 25281467Free PMC article.Review.

5.

Extended Versus Limited Lymph Node Dissection in Bladder Cancer Patients Undergoing Radical Cystectomy: Survival Results from a Prospective, Randomized Trial.

Gschwend JE, Heck MM, Lehmann J, Rübben H, Albers P, Wolff JM, Frohneberg D, de Geeter P, Heidenreich A, Kälble T, Stöckle M, Schnöller T, Stenzl A, Müller M, Truss M, Roth S, Liehr UB, Leißner J, Bregenzer T, Retz M.

Eur Urol. 2019 Apr;75(4):604-611. doi: 10.1016/j.eururo.2018.09.047. Epub 2018 Oct 15.

PMID: 30337060Clinical Trial.

6.

Immune checkpoint inhibition for the treatment of renal cell carcinoma.

Stühler V, Maas JM, Rausch S, Stenzl A, Bedke J.

Expert Opin Biol Ther. 2020 Jan;20(1):83-94. doi: 10.1080/14712598.2020.1677601. Epub 2019 Oct 13.

PMID: 31587590Review.

7.

A systematic review and meta-analysis on the oncological long-term outcomes after trimodality therapy and radical cystectomy with or without neoadjuvant chemotherapy for muscle-invasive bladder cancer.

Fahmy O, Khairul-Asri MG, Schubert T, Renninger M, Malek R, Kübler H, Stenzl A, Gakis G.

Urol Oncol. 2018 Feb;36(2):43-53. doi: 10.1016/j.urolonc.2017.10.002. Epub 2017 Nov 6.

PMID: 29102254Review.

8.

Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma.

Motzer RJ, Haas NB, Donskov F, Gross-Goupil M, Varlamov S, Kopyltsov E, Lee JL, Melichar B, Rini BI, Choueiri TK, Zemanova M, Wood LA, Reaume MN, Stenzl A, Chowdhury S, Lim HY, McDermott R, Michael A, Bao W, Carrasco-Alfonso MJ, Aimone P, Voi M, Doehn C, Russo P, Sternberg CN; PROTECT investigators.

J Clin Oncol. 2017 Dec 10;35(35):3916-3923. doi: 10.1200/JCO.2017.73.5324. Epub 2017 Sep 13.

PMID: 28902533Free PMC article.Clinical Trial.

9.

Inmunotherapy in prostate cancer.

Anselmo da Costa I, Stenzl A, Bedke J.

Arch Esp Urol. 2019 Mar;72(2):211-222.

PMID: 30855023Review.English.

10.

Non-visible haematuria for the Detection of Bladder, Upper Tract, and Kidney Cancer: An Updated Systematic Review and Meta-analysis.

Jubber I, Shariat SF, Conroy S, Tan WS, Gordon PC, Lotan Y, Messing EM, Stenzl A, Rhijn BV, Kelly JD, Catto JWF, Cumberbatch MG.

Eur Urol. 2020 May;77(5):583-598. doi: 10.1016/j.eururo.2019.10.010. Epub 2019 Nov 30.

PMID: 31791622Review.

11.

Can urinary biomarkers replace cystoscopy?

Maas M, Bedke J, Stenzl A, Todenhöfer T.

World J Urol. 2019 Sep;37(9):1741-1749. doi: 10.1007/s00345-018-2505-2. Epub 2018 Oct 3.

PMID: 30283995Review.

12.

Selective Inhibition of the Lactate Transporter MCT4 Reduces Growth of Invasive Bladder Cancer.

Todenhöfer T, Seiler R, Stewart C, Moskalev I, Gao J, Ladhar S, Kamjabi A, Al Nakouzi N, Hayashi T, Choi S, Wang Y, Frees S, Daugaard M, Oo HZ, Fisel P, Schwab M, Schaeffeler E, Douglas J, Hennenlotter J, Bedke J, Gibb EA, Fazli L, Stenzl A, Black PC.

Mol Cancer Ther. 2018 Dec;17(12):2746-2755. doi: 10.1158/1535-7163.MCT-18-0107. Epub 2018 Sep 27.

PMID: 30262589

13.

PD-1 and LAG-3 Dominate Checkpoint Receptor-Mediated T-cell Inhibition in Renal Cell Carcinoma.

Zelba H, Bedke J, Hennenlotter J, Mostböck S, Zettl M, Zichner T, Chandran A, Stenzl A, Rammensee HG, Gouttefangeas C.

Cancer Immunol Res. 2019 Nov;7(11):1891-1899. doi: 10.1158/2326-6066.CIR-19-0146. Epub 2019 Sep 4.

PMID: 31484656

14.

Clinical Parameters Outperform Molecular Subtypes for Predicting Outcome in Bladder Cancer: Results from Multiple Cohorts, Including TCGA.

Morera DS, Hasanali SL, Belew D, Ghosh S, Klaassen Z, Jordan AR, Wang J, Terris MK, Bollag RJ, Merseburger AS, Stenzl A, Soloway MS, Lokeshwar VB.

J Urol. 2020 Jan;203(1):62-72. doi: 10.1097/JU.0000000000000351. Epub 2019 May 21.

PMID: 31112107

15.

EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort: Under the Auspices of the EAU-ESMO Guidelines Committees.

Witjes JA, Babjuk M, Bellmunt J, Bruins HM, De Reijke TM, De Santis M, Gillessen S, James N, Maclennan S, Palou J, Powles T, Ribal MJ, Shariat SF, Der Kwast TV, Xylinas E, Agarwal N, Arends T, Bamias A, Birtle A, Black PC, Bochner BH, Bolla M, Boormans JL, Bossi A, Briganti A, Brummelhuis I, Burger M, Castellano D, Cathomas R, Chiti A, Choudhury A, Compérat E, Crabb S, Culine S, De Bari B, De Blok W, J L De Visschere P, Decaestecker K, Dimitropoulos K, Dominguez-Escrig JL, Fanti S, Fonteyne V, Frydenberg M, Futterer JJ, Gakis G, Geavlete B, Gontero P, Grubmüller B, Hafeez S, Hansel DE, Hartmann A, Hayne D, Henry AM, Hernandez V, Herr H, Herrmann K, Hoskin P, Huguet J, Jereczek-Fossa BA, Jones R, Kamat AM, Khoo V, Kiltie AE, Krege S, Ladoire S, Lara PC, Leliveld A, Linares-Espinós E, Løgager V, Lorch A, Loriot Y, Meijer R, Mir MC, Moschini M, Mostafid H, Müller AC, Müller CR, N'Dow J, Necchi A, Neuzillet Y, Oddens JR, Oldenburg J, Osanto S, J G Oyen W, Pacheco-Figueiredo L, Pappot H, Patel MI, Pieters BR, Plass K, Remzi M, Retz M, Richenberg J, Rink M, Roghmann F, Rosenberg JE, Rouprêt M, Rouvière O, Salembier C, Salminen A, Sargos P, Sengupta S, Sherif A, Smeenk RJ, Smits A, Stenzl A, Thalmann GN, Tombal B, Turkbey B, Lauridsen SV, Valdagni R, Van Der Heijden AG, Van Poppel H, Vartolomei MD, Veskimäe E, Vilaseca A, Rivera FAV, Wiegel T, Wiklund P, Williams A, Zigeuner R, Horwich A.

Eur Urol. 2020 Feb;77(2):223-250. doi: 10.1016/j.eururo.2019.09.035. Epub 2019 Nov 19.

PMID: 31753752

16.

Immunotherapy for kidney cancer: status quo and the future.

Bedke J, Stühler V, Stenzl A, Brehmer B.

Curr Opin Urol. 2018 Jan;28(1):8-14. doi: 10.1097/MOU.0000000000000466.

PMID: 29120911Review.

17.

Molecular predictors of response to PD-1/PD-L1 inhibition in urothelial cancer.

Stühler V, Maas JM, Bochem J, da Costa IA, Todenhöfer T, Stenzl A, Bedke J.

World J Urol. 2019 Sep;37(9):1773-1784. doi: 10.1007/s00345-018-2538-6. Epub 2018 Oct 29.

PMID: 30374610Review.

18.

Reply to Santhanam Sundar's letter to the editor Re: Arnulf Stenzl, Nigel C. Cowan, Maria De Santis, et al. Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. Eur Urol 2011;59:1009-18.

Stenzl A, Cowan NC, De Santis M, Kuczyk MA, Merseburger AS, Ribal MJ, Sherif A, Witjes JA, Lebret T.

Eur Urol. 2012 Aug;62(2):e45-6. doi: 10.1016/j.eururo.2012.04.042. Epub 2012 May 3.

PMID: 22579356No abstract available.

19.

Prognostic and Prediction Tools in Bladder Cancer: A Comprehensive Review of the Literature.

Kluth LA, Black PC, Bochner BH, Catto J, Lerner SP, Stenzl A, Sylvester R, Vickers AJ, Xylinas E, Shariat SF.

Eur Urol. 2015 Aug;68(2):238-53. doi: 10.1016/j.eururo.2015.01.032. Epub 2015 Feb 21.

PMID: 25709027Review.

20.

Editorial Comment.

Stenzl A.

J Urol. 2018 May;199(5):1165. doi: 10.1016/j.juro.2017.11.147. Epub 2018 Feb 16.

PMID: 29458033No abstract available.

21.

Bone Health Issues in Patients with Prostate Cancer: An Evidence-Based Review.

Walz S, Maas M, Stenzl A, Todenhöfer T.

World J Mens Health. 2020 Apr;38(2):151-163. doi: 10.5534/wjmh.190044. Epub 2019 May 2.

PMID: 31081297Free PMC article.Review.

22.

Pathophysiology and Contributing Factors in Postprostatectomy Incontinence: A Review.

Heesakkers J, Farag F, Bauer RM, Sandhu J, De Ridder D, Stenzl A.

Eur Urol. 2017 Jun;71(6):936-944. doi: 10.1016/j.eururo.2016.09.031. Epub 2016 Oct 6.

PMID: 27720536Review.

23.

The Role of Radical Prostatectomy and Radiotherapy in Treatment of Locally Advanced Prostate Cancer: A Systematic Review and Meta-Analysis.

Fahmy O, Khairul-Asri MG, Hadi SHSM, Gakis G, Stenzl A.

Urol Int. 2017;99(3):249-256. doi: 10.1159/000478789. Epub 2017 Jul 4.

PMID: 28675891Review.

24.

SIU-ICUD consultation on bladder cancer: treatment of muscle-invasive bladder cancer.

Leow JJ, Bedke J, Chamie K, Collins JW, Daneshmand S, Grivas P, Heidenreich A, Messing EM, Royce TJ, Sankin AI, Schoenberg MP, Shipley WU, Villers A, Efstathiou JA, Bellmunt J, Stenzl A.

World J Urol. 2019 Jan;37(1):61-83. doi: 10.1007/s00345-018-2606-y. Epub 2019 Jan 25.

PMID: 30684034Review.

25.

Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1.

Smith M, De Bono J, Sternberg C, Le Moulec S, Oudard S, De Giorgi U, Krainer M, Bergman A, Hoelzer W, De Wit R, Bögemann M, Saad F, Cruciani G, Thiery-Vuillemin A, Feyerabend S, Miller K, Houédé N, Hussain S, Lam E, Polikoff J, Stenzl A, Mainwaring P, Ramies D, Hessel C, Weitzman A, Fizazi K.

J Clin Oncol. 2016 Sep 1;34(25):3005-13. doi: 10.1200/JCO.2015.65.5597. Epub 2016 Jul 11.

PMID: 27400947Clinical Trial.

26.

Urethral recurrence after radical cystectomy for urothelial carcinoma: A systematic review and meta-analysis.

Fahmy O, Khairul-Asri MG, Schubert T, Renninger M, Kübler H, Stenzl A, Gakis G.

Urol Oncol. 2018 Feb;36(2):54-59. doi: 10.1016/j.urolonc.2017.11.007. Epub 2017 Nov 28.

PMID: 29196179Review.

27.

Expression of Epithelial Mesenchymal Transition and Cancer Stem Cell Markers in Circulating Tumor Cells.

Werner S, Stenzl A, Pantel K, Todenhöfer T.

Adv Exp Med Biol. 2017;994:205-228. doi: 10.1007/978-3-319-55947-6_11.

PMID: 28560676Review.

28.

Prospective Validation of an mRNA-based Urine Test for Surveillance of Patients with Bladder Cancer.

Valenberg FJPV, Hiar AM, Wallace E, Bridge JA, Mayne DJ, Beqaj S, Sexton WJ, Lotan Y, Weizer AZ, Jansz GK, Stenzl A, Danella JF, Shepard B, Cline KJ, Williams MB, Montgomery S, David RD, Harris R, Klein EW, Bradford TJ, Wolk FN, Westenfelder KR, Trainer AF, Richardson TA, Egerdie RB, Goldfarb B, Zadra JA, Ge S, Zhao S, Simon IM, Campbell SA, Rhees B, Bates MP, Higuchi RG, Witjes JA.

Eur Urol. 2019 May;75(5):853-860. doi: 10.1016/j.eururo.2018.11.055. Epub 2018 Dec 12.

PMID: 30553612

29.

Enhanced Recovery After Robot-assisted Radical Cystectomy: EAU Robotic Urology Section Scientific Working Group Consensus View.

Collins JW, Patel H, Adding C, Annerstedt M, Dasgupta P, Khan SM, Artibani W, Gaston R, Piechaud T, Catto JW, Koupparis A, Rowe E, Perry M, Issa R, McGrath J, Kelly J, Schumacher M, Wijburg C, Canda AE, Balbay MD, Decaestecker K, Schwentner C, Stenzl A, Edeling S, Pokupić S, Stockle M, Siemer S, Sanchez-Salas R, Cathelineau X, Weston R, Johnson M, D'Hondt F, Mottrie A, Hosseini A, Wiklund PN.

Eur Urol. 2016 Oct;70(4):649-660. doi: 10.1016/j.eururo.2016.05.020. Epub 2016 May 24.

PMID: 27234997Review.

30.

The economics of bladder cancer: costs and considerations of caring for this disease.

Svatek RS, Hollenbeck BK, Holmäng S, Lee R, Kim SP, Stenzl A, Lotan Y.

Eur Urol. 2014 Aug;66(2):253-62. doi: 10.1016/j.eururo.2014.01.006. Epub 2014 Jan 21.

PMID: 24472711Review.

31.

Characterization of the breast cancer resistance protein (BCRP/ABCG2) in clear cell renal cell carcinoma.

Reustle A, Fisel P, Renner O, Büttner F, Winter S, Rausch S, Kruck S, Nies AT, Hennenlotter J, Scharpf M, Fend F, Stenzl A, Bedke J, Schwab M, Schaeffeler E.

Int J Cancer. 2018 Dec 15;143(12):3181-3193. doi: 10.1002/ijc.31741. Epub 2018 Sep 25.

PMID: 30070687

32.

[Immune checkpoint inhibition in metastatic urothelial carcinoma].

Bedke J, Todenhöfer T, Stenzl A.

Aktuelle Urol. 2018 Apr;49(2):178-186. doi: 10.1055/a-0581-4395. Epub 2018 Mar 27.

PMID: 29587323Review.German.

33.

Stress urinary incontinence and regenerative medicine: is injecting functional cells into the urethra feasible based on current knowledge and future prospects?

Aufderklamm S, Aicher WK, Amend B, Stenzl A.

Curr Opin Urol. 2019 Jul;29(4):394-399. doi: 10.1097/MOU.0000000000000624.

PMID: 31033573Review.

34.

A Subpopulation of Stromal Cells Controls Cancer Cell Homing to the Bone Marrow.

Rossnagl S, Ghura H, Groth C, Altrock E, Jakob F, Schott S, Wimberger P, Link T, Kuhlmann JD, Stenzl A, Hennenlotter J, Todenhöfer T, Rojewski M, Bieback K, Nakchbandi IA.

Cancer Res. 2018 Jan 1;78(1):129-142. doi: 10.1158/0008-5472.CAN-16-3507. Epub 2017 Oct 24.

PMID: 29066511

35.

Complication rate after cystectomy following pelvic radiotherapy: an international, multicenter, retrospective series of 682 cases.

Gontero P, Pisano F, Palou J, Joniau S, Albersen M, Colombo R, Briganti A, Pellucchi F, Faba OR, van Rhijn BW, van de Putte EF, Babjuk M, Fritsche HM, Mayr R, Albers P, Niegisch G, Anract J, Masson-Lecomte A, De la Taille A, Roupret M, Peyronnet B, Cai T, Witjes AJ, Bruins M, Baniel J, Mano R, Lapini A, Sessa F, Irani J, Brausi M, Stenzl A, Karnes JR, Scherr D, O'Malley P, Taylor B, Shariat SF, Black P, Abdi H, Matveev VB, Samuseva O, Parekh D, Gonzalgo M, Vetterlein MW, Aziz A, Fisch M, Catto J, Pang KH, Xylinas E, Rink M; Young Academic Urologists Urothelial Carcinoma Group of the European Association of Urology.

World J Urol. 2020 Aug;38(8):1959-1968. doi: 10.1007/s00345-019-02982-6. Epub 2019 Nov 6.

PMID: 31691084

36.

Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder Cancer.

Vandekerkhove G, Todenhöfer T, Annala M, Struss WJ, Wong A, Beja K, Ritch E, Brahmbhatt S, Volik SV, Hennenlotter J, Nykter M, Chi KN, North S, Stenzl A, Collins CC, Eigl BJ, Black PC, Wyatt AW.

Clin Cancer Res. 2017 Nov 1;23(21):6487-6497. doi: 10.1158/1078-0432.CCR-17-1140. Epub 2017 Jul 31.

PMID: 28760909

37.

Single-use versus reusable ureterorenoscopes for retrograde intrarenal surgery (RIRS): systematic comparative analysis of physical and optical properties in three different devices.

Deininger S, Haberstock L, Kruck S, Neumann E, da Costa IA, Todenhöfer T, Bedke J, Stenzl A, Rausch S.

World J Urol. 2018 Dec;36(12):2059-2063. doi: 10.1007/s00345-018-2365-9. Epub 2018 Jun 5.

PMID: 29869701

38.

Intratumoral Heterogeneity Determines the Expression of mTOR-pathway Proteins in Prostate Cancer.

Russo GI, Hennenlotter J, Vogel U, Kühs U, Wurm TM, Gerber V, Neumann T, Cimino S, Stenzl A, Todenhöfer T.

Dis Markers. 2019 Dec 11;2019:1296865. doi: 10.1155/2019/1296865. eCollection 2019.

PMID: 31885728 Free PMC article.

39.

European Association of Urology Guidelines Office Rapid Reaction Group: An Organisation-wide Collaborative Effort to Adapt the European Association of Urology Guidelines Recommendations to the Coronavirus Disease 2019 Era.

Ribal MJ, Cornford P, Briganti A, Knoll T, Gravas S, Babjuk M, Harding C, Breda A, Bex A; GORRG Group, Rassweiler JJ, Gözen AS, Pini G, Liatsikos E, Giannarini G, Mottrie A, Subramaniam R, Sofikitis N, Rocco BMC, Xie LP, Witjes JA, Mottet N, Ljungberg B, Rouprêt M, Laguna MP, Salonia A, Bonkat G, Blok BFM, Türk C, Radmayr C, Kitrey ND, Engeler DS, Lumen N, Hakenberg OW, Watkin N, Hamid R, Olsburgh J, Darraugh J, Shepherd R, Smith EJ, Chapple CR, Stenzl A, Van Poppel H, Wirth M, Sønksen J, N'Dow J; EAU Section Offices and the EAU Guidelines Panels.

Eur Urol. 2020 Jul;78(1):21-28. doi: 10.1016/j.eururo.2020.04.056. Epub 2020 Apr 27.

PMID: 32376137 Free PMC article.

40.

NLRP3/IL1β inflammasome associated with the aging bladder triggers bladder dysfunction in female rats.

Chen L, He PL, Yang J, Yang YF, Wang K, Amend B, Stenzl A, Zhang YM, Wang ZL, Xing SS, Luo X.

Mol Med Rep. 2019 Apr;19(4):2960-2968. doi: 10.3892/mmr.2019.9919. Epub 2019 Jan 31.

PMID: 30720125 Free PMC article.

41.

Comparison of 68Ga-labelled PSMA-11 and 11C-choline in the detection of prostate cancer metastases by PET/CT.

Schwenck J, Rempp H, Reischl G, Kruck S, Stenzl A, Nikolaou K, Pfannenberg C, la Fougère C.

Eur J Nucl Med Mol Imaging. 2017 Jan;44(1):92-101. doi: 10.1007/s00259-016-3490-6. Epub 2016 Aug 24.

PMID: 27557844

42.

Preservation of the bladder, but at what cost?

Harland N, Stenzl A.

Transl Androl Urol. 2019 Dec;8(Suppl 5):S474-S475. doi: 10.21037/tau.2019.09.40.

PMID: 32042621Free PMC article.No abstract available.

43.

Intention-to-Treat Analysis of 68Ga-PSMA and 11C-Choline PET/CT Versus CT for Prostate Cancer Recurrence After Surgery.

Schwenck J, Olthof SC, Pfannenberg C, Reischl G, Wegener D, Marzec J, Bedke J, Stenzl A, Nikolaou K, la Fougère C, Zips D, Müller AC.

J Nucl Med. 2019 Oct;60(10):1359-1365. doi: 10.2967/jnumed.118.224543. Epub 2019 Mar 8.

PMID: 30850491

44.

IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial.

Rini BI, Stenzl A, Zdrojowy R, Kogan M, Shkolnik M, Oudard S, Weikert S, Bracarda S, Crabb SJ, Bedke J, Ludwig J, Maurer D, Mendrzyk R, Wagner C, Mahr A, Fritsche J, Weinschenk T, Walter S, Kirner A, Singh-Jasuja H, Reinhardt C, Eisen T.

Lancet Oncol. 2016 Nov;17(11):1599-1611. doi: 10.1016/S1470-2045(16)30408-9. Epub 2016 Oct 3.

PMID: 27720136Clinical Trial.

45.

Regenerative medicine and injection therapies in stress urinary incontinence.

Hillary CJ, Roman S, MacNeil S, Aicher WK, Stenzl A, Chapple CR.

Nat Rev Urol. 2020 Mar;17(3):151-161. doi: 10.1038/s41585-019-0273-4. Epub 2020 Jan 23.

PMID: 31974507Review.

46.

Immune Checkpoint Inhibition in Metastatic Urothelial Cancer.

Powles T, Smith K, Stenzl A, Bedke J.

Eur Urol. 2017 Oct;72(4):477-481. doi: 10.1016/j.eururo.2017.03.047. Epub 2017 Apr 14.

PMID: 28413128

47.

[Immunotherapy with checkpoint inhibitors in local advanced and metastatic urothelial carcinoma].

Miller K, Gschwend JE, Merseburger A, Retz M, Stenzl A.

Aktuelle Urol. 2018 Apr;49(2):142-156. doi: 10.1055/s-0043-123067. Epub 2018 Mar 27.

PMID: 29587321Review.German.

48.

Effect of Enzalutamide plus Androgen Deprivation Therapy on Health-related Quality of Life in Patients with Metastatic Hormone-sensitive Prostate Cancer: An Analysis of the ARCHES Randomised, Placebo-controlled, Phase 3 Study.

Stenzl A, Dunshee C, De Giorgi U, Alekseev B, Iguchi T, Szmulewitz RZ, Flaig TW, Tombal B, Morlock R, Ivanescu C, Ramaswamy K, Saad F, Armstrong AJ.

Eur Urol. 2020 Oct;78(4):603-614. doi: 10.1016/j.eururo.2020.03.019. Epub 2020 Apr 23.

PMID: 32336645

49.

Should every patient with muscle-invasive bladder cancer receive neoadjuvant chemotherapy?

Maas M, Stenzl A.

Transl Androl Urol. 2019 Jul;8(Suppl 3):S274-S276. doi: 10.21037/tau.2019.03.03.

PMID: 31392143Free PMC article.No abstract available.

50.

Molecular markers in disease detection and follow-up of patients with non-muscle invasive bladder cancer.

Maas M, Walz S, Stühler V, Aufderklamm S, Rausch S, Bedke J, Stenzl A, Todenhöfer T.

Expert Rev Mol Diagn. 2018 May;18(5):443-455. doi: 10.1080/14737159.2018.1469979.

PMID: 29707982Review.

51.

Author'S reply.

Sim A, Todenhöfer T, Mischinger J, Halalsheh O, Boettge J, Rausch S, Bier S, Aufderklamm S, Stenzl A, Gakis G, Schwentner C.

Cent European J Urol. 2014;67(4):426. doi: 10.5173/ceju.2014.04.art23.

PMID: 25667769Free PMC article.No abstract available.

52.

Uroonkologie des Harntrakts - Spätrezidive nach Urothelkarzinom der Blase.

Stenzl A.

Aktuelle Urol. 2014 Nov;45(6):434-5. doi: 10.1055/s-0034-1397280. Epub 2014 Dec 16.

PMID: 25514773German.No abstract available.

53.

Circulating tumor cells and their role in prostate cancer.

Maas M, Hegemann M, Rausch S, Bedke J, Stenzl A, Todenhöfer T.

Asian J Androl. 2017 Aug 22;21(1):24-31. doi: 10.4103/aja.aja_29_17. Online ahead of print.

PMID: 28836508Free PMC article.Review.

54.

[Reconstructive surgery of the urinary bladder].

Schnürer S, Amend B, Stenzl A, Rausch S.

Aktuelle Urol. 2017 Dec;48(6):561-568. doi: 10.1055/s-0043-104508. Epub 2017 Jun 14.

PMID: 28614853German.

55.

Urinary diversion.

World Health Organization (WHO) Consensus Conference on Bladder Cancer, Hautmann RE, Abol-Enein H, Hafez K, Haro I, Mansson W, Mills RD, Montie JD, Sagalowsky AI, Stein JP, Stenzl A, Studer UE, Volkmer BG.

Urology. 2007 Jan;69(1 Suppl):17-49. doi: 10.1016/j.urology.2006.05.058.

PMID: 17280907Review.

56.

Immunotherapeutic strategies for the treatment of renal cell carcinoma: Where will we go?

Anselmo Da Costa I, Rausch S, Kruck S, Todenhöfer T, Stenzl A, Bedke J.

Expert Rev Anticancer Ther. 2017 Apr;17(4):357-368. doi: 10.1080/14737140.2017.1292138. Epub 2017 Feb 20.

PMID: 28162024Review.

57.

Monitoring high-risk bladder cancer.

Schwentner C, Stenzl A, Gakis G.

Curr Opin Urol. 2012 Sep;22(5):421-6. doi: 10.1097/MOU.0b013e3283555d04.

PMID: 22814882Review.

58.

Higher prevalence of lymph node metastasis in prostate cancer in patients with diabetes.

Lutz SZ, Todenhöfer T, Wagner R, Hennenlotter J, Ferchl JM, Scharpf MO, Martus P, Staiger H, Fritsche A, Stenzl A, Häring HU, Heni M.

Endocr Relat Cancer. 2018 Mar;25(3):L19-L22. doi: 10.1530/ERC-17-0465. Epub 2018 Jan 12.

PMID: 29330196No abstract available.

59.

Vordere Exenteration der Frau.

Amend B, Schilling D, Bedke J, Stenzl A.

Aktuelle Urol. 2020 Apr;51(2):202-216. doi: 10.1055/a-1017-4850. Epub 2020 Mar 24.

PMID: 32208515German.No abstract available.

60.

Considerations for orthotopic diversions in women.

Gakis G, Stenzl A.

Curr Opin Urol. 2015 Nov;25(6):550-4. doi: 10.1097/MOU.0000000000000224.

PMID: 26375059Review.

61.

Robotic intracorporeal urinary diversion: practical review of current surgical techniques.

Dal Moro F, Haber GP, Wiklund P, Canda AE, Balbay MD, Stenzl A, Zattoni F, Palou J, Gill I, Catto JW.

Minerva Urol Nefrol. 2017 Feb;69(1):14-25. doi: 10.23736/S0393-2249.16.02780-6. Epub 2016 Aug 31.

PMID: 28009143Review.

62.

Liquid biopsy: ready to guide therapy in advanced prostate cancer?

Hegemann M, Stenzl A, Bedke J, Chi KN, Black PC, Todenhöfer T.

BJU Int. 2016 Dec;118(6):855-863. doi: 10.1111/bju.13586. Epub 2016 Aug 19.

PMID: 27430478Review.

63.

Optical improvements in the diagnosis of bladder cancer: implications for clinical practice.

Schubert T, Rausch S, Fahmy O, Gakis G, Stenzl A.

Ther Adv Urol. 2017 Sep 4;9(11):251-260. doi: 10.1177/1756287217720401. eCollection 2017 Nov.

PMID: 29662543Free PMC article.Review.

64.

The current status of checkpoint inhibitors in metastatic bladder cancer.

Fahmy O, Khairul-Asri MG, Stenzl A, Gakis G.

Clin Exp Metastasis. 2016 Oct;33(7):629-35. doi: 10.1007/s10585-016-9807-9. Epub 2016 Jul 5.

PMID: 27380916Review.

65.

Mesenchymal stromal cells for sphincter regeneration.

Klein G, Hart ML, Brinchmann JE, Rolauffs B, Stenzl A, Sievert KD, Aicher WK.

Adv Drug Deliv Rev. 2015 Mar;82-83:123-36. doi: 10.1016/j.addr.2014.10.026. Epub 2014 Oct 27.

PMID: 25451135Review.

66.

Thymidine kinase and cancer monitoring.

Aufderklamm S, Todenhöfer T, Gakis G, Kruck S, Hennenlotter J, Stenzl A, Schwentner C.

Cancer Lett. 2012 Mar;316(1):6-10. doi: 10.1016/j.canlet.2011.10.025. Epub 2011 Nov 6.

PMID: 22068047Review.

67.

Current concepts and trends in the treatment of bone metastases in patients with advanced prostate cancer.

Hegemann M, Maas M, Rausch S, Walz S, Bedke J, Stenzl A, Todenhöfer T.

Asian J Androl. 2017 Dec 29;21(1):12-8. doi: 10.4103/aja.aja_59_17. Online ahead of print.

PMID: 29286005Free PMC article.Review.

68.

Looking forward, looking back-10 years in urology.

Albersen M, Cartwright R, Choyke P, Goldenberg SL, Goldman H, Lawrentschuk N, Linehan WM, Murphy D, Nagler H, Scardino P, Shortliffe L, Stenzl A, Theodorescu D.

Nat Rev Urol. 2014 Nov;11(11):649-55. doi: 10.1038/nrurol.2014.263. Epub 2014 Oct 28.

PMID: 25348169Review.

69.

Systematic Review on the Fate of the Remnant Urothelium after Radical Cystectomy.

Gakis G, Black PC, Bochner BH, Boorjian SA, Stenzl A, Thalmann GN, Kassouf W.

Eur Urol. 2017 Apr;71(4):545-557. doi: 10.1016/j.eururo.2016.09.035. Epub 2016 Oct 6.

PMID: 27720534Free PMC article.Review.

70.

Transketolase like 1 (TKTL1) expression alterations in prostate cancer tumorigenesis.

da Costa IA, Hennenlotter J, Stühler V, Kühs U, Scharpf M, Todenhöfer T, Stenzl A, Bedke J.

Urol Oncol. 2018 Oct;36(10):472.e21-472.e27. doi: 10.1016/j.urolonc.2018.06.010. Epub 2018 Aug 16.

PMID: 30119993

71.

EAU policy on live surgery events.

Artibani W, Ficarra V, Challacombe BJ, Abbou CC, Bedke J, Boscolo-Berto R, Brausi M, de la Rosette JJ, Deger S, Denis L, Guazzoni G, Guillonneau B, Heesakkers JP, Jacqmin D, Knoll T, Martínez-Piñeiro L, Montorsi F, Mottrie A, Piechaud PT, Rane A, Rassweiler J, Stenzl A, Van Moorselaar J, Van Velthoven RF, van Poppel H, Wirth M, Abrahamsson PA, Parsons KF.

Eur Urol. 2014 Jul;66(1):87-97. doi: 10.1016/j.eururo.2014.01.028. Epub 2014 Jan 30.

PMID: 24560818Review.

72.

Denosumab treatment in the management of patients with advanced prostate cancer: clinical evidence and experience.

Hegemann M, Bedke J, Stenzl A, Todenhöfer T.

Ther Adv Urol. 2017 Feb 6;9(3-4):81-88. doi: 10.1177/1756287216686018. eCollection 2017 Mar-Apr.

PMID: 28392837Free PMC article.Review.

73.

Adjuvant Treatment of High-risk Renal Cell Carcinoma: Leaving the Desert?

Kroeger N, Stenzl A, Burchardt M, Bedke J.

Eur Urol. 2017 May;71(5):695-696. doi: 10.1016/j.eururo.2016.10.023. Epub 2016 Oct 27.

PMID: 28085669

74.

Transurethral Resection of Bladder Tumors: Next-generation Virtual Reality Training for Surgeons.

Neumann E, Mayer J, Russo GI, Amend B, Rausch S, Deininger S, Harland N, da Costa IA, Hennenlotter J, Stenzl A, Kruck S, Bedke J.

Eur Urol Focus. 2019 Sep;5(5):906-911. doi: 10.1016/j.euf.2018.04.011. Epub 2018 May 22.

PMID: 29802051

75.

Algorithm for Optimal Urethral Coverage in Hypospadias and Fistula Repair: A Systematic Review.

Fahmy O, Khairul-Asri MG, Schwentner C, Schubert T, Stenzl A, Zahran MH, Gakis G.

Eur Urol. 2016 Aug;70(2):293-8. doi: 10.1016/j.eururo.2015.12.047. Epub 2016 Jan 15.

PMID: 26776935Review.

76.

Systemic Alterations of Wnt Inhibitors in Patients with Prostate Cancer and Bone Metastases.

Aufderklamm S, Hennenlotter J, Leidenberger P, Rausch S, Hohneder A, Kühs U, Maas M, Schwentner C, Bedke J, Stenzl A, Todenhöfer T.

Dis Markers. 2018 Jul 18;2018:1874598. doi: 10.1155/2018/1874598. eCollection 2018.

PMID: 30116403 Free PMC article.

77.

Inflammation and Cancer: What Can We Therapeutically Expect from Checkpoint Inhibitors?

Mischinger J, Comperat E, Schwentner C, Stenzl A, Gakis G.

Curr Urol Rep. 2015 Sep;16(9):59. doi: 10.1007/s11934-015-0532-8.

PMID: 26141938Review.

78.

Checkpoint modulation--A new way to direct the immune system against renal cell carcinoma.

Bedke J, Kruck S, Gakis G, Stenzl A, Goebell PJ.

Hum Vaccin Immunother. 2015;11(5):1201-8. doi: 10.1080/21645515.2015.1016657.

PMID: 25912622Free PMC article.Review.

79.

Does it matter whether a T1 high-grade tumor is molecularly classified?

Stenzl A, McConkey D, Bellmunt J.

Eur Urol Oncol. 2019 Aug 3:S2588-9311(19)30112-9. doi: 10.1016/j.euo.2019.07.009. Online ahead of print.

PMID: 31383572

80.

Peptide-Based Sandwich Immunoassay for the Quantification of the Membrane Transporter Multidrug Resistance Protein 1.

Poetz O, Dieze T, Hammer H, Weiß F, Sommersdorf C, Templin MF, Esdar C, Zimmermann A, Stevanovic S, Bedke J, Stenzl A, Joos TO.

Anal Chem. 2018 May 1;90(9):5788-5794. doi: 10.1021/acs.analchem.8b00152. Epub 2018 Apr 12.

PMID: 29570278

81.

Targeted vs systematic robot-assisted transperineal magnetic resonance imaging-transrectal ultrasonography fusion prostate biopsy.

Mischinger J, Kaufmann S, Russo GI, Harland N, Rausch S, Amend B, Scharpf M, Loewe L, Todenhoefer T, Notohamiprodjo M, Nikolaou K, Stenzl A, Bedke J, Kruck S.

BJU Int. 2018 May;121(5):791-798. doi: 10.1111/bju.14089. Epub 2018 Jan 15.

PMID: 29211932

82.

Update of the ICUD-SIU consultation on upper tract urothelial carcinoma 2016: treatment of localized high-risk disease.

Gakis G, Schubert T, Alemozaffar M, Bellmunt J, Bochner BH, Boorjian SA, Daneshmand S, Huang WC, Kondo T, Konety BR, Laguna MP, Matin SF, Siefker-Radtke AO, Shariat SF, Stenzl A.

World J Urol. 2017 Mar;35(3):327-335. doi: 10.1007/s00345-016-1819-1. Epub 2016 Apr 4.

PMID: 27043218Review.

83.

Determination of Free-PSA (fPSA) and fPSA/PSA-Ratio Using A Point-of-Care Device.

Costa IAD, Hennenlotter J, Todenhöfer T, Neumann E, Deininger S, Aufderklamm S, Bedke J, Stenzl A, Rausch S.

Clin Lab. 2019 Jan 1;65(1). doi: 10.7754/Clin.Lab.2018.180710.

PMID: 30775903

84.

Editorial comment.

Stenzl A.

J Urol. 2010 Oct;184(4):1300. doi: 10.1016/j.juro.2010.06.060. Epub 2010 Aug 17.

PMID: 20723916No abstract available.

85.

Targeting bone metabolism in patients with advanced prostate cancer: current options and controversies.

Todenhöfer T, Stenzl A, Hofbauer LC, Rachner TD.

Int J Endocrinol. 2015;2015:838202. doi: 10.1155/2015/838202. Epub 2015 Jan 31.

PMID: 25802521Free PMC article.Review.

86.

Current status of robotic assisted radical cystectomy with intracorporeal ileal neobladder for bladder cancer.

Fahmy O, Asri K, Schwentner C, Stenzl A, Gakis G.

J Surg Oncol. 2015 Sep;112(4):427-9. doi: 10.1002/jso.24007. Epub 2015 Aug 11.

PMID: 26265262Review.

87.

Calgranulin A (S100A8) Immunostaining: A Future Candidate for Risk Assessment in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC).

Nicklas AP, Kramer MW, Serth J, Hennenlotter J, Hupe MC, Reimer DU, Stenzl A, Merseburger AS, Kuczyk MA, von Klot CJ.

Adv Ther. 2018 Nov;35(11):2054-2068. doi: 10.1007/s12325-018-0789-7. Epub 2018 Sep 19.

PMID: 30232708 Free PMC article.

88.

Expression of tumour progression-associated genes in circulating tumour cells of patients at different stages of prostate cancer.

Russo GI, Bier S, Hennenlotter J, Beger G, Pavlenco L, van de Flierdt J, Hauch S, Maas M, Walz S, Rausch S, Bedke J, Morgia G, Stenzl A, Todenhöfer T.

BJU Int. 2018 Jul;122(1):152-159. doi: 10.1111/bju.14200. Epub 2018 Apr 10.

PMID: 29542849

89.

mRNA vaccine CV9103 and CV9104 for the treatment of prostate cancer.

Rausch S, Schwentner C, Stenzl A, Bedke J.

Hum Vaccin Immunother. 2014;10(11):3146-52. doi: 10.4161/hv.29553.

PMID: 25483661Free PMC article.Review.

90.

Evolution of the concept of androgen-sensitive bladder cancer.

Gakis G, Stenzl A, Renninger M.

Scand J Urol. 2013 Jun;47(3):173-8. doi: 10.3109/00365599.2012.756929. Epub 2013 Jan 21.

PMID: 23330817Review.

91.

Cognitive versus Software-Assisted Registration: Development of a New Nomogram Predicting Prostate Cancer at MRI-Targeted Biopsies.

Kaufmann S, Russo GI, Thaiss W, Notohamiprodjo M, Bamberg F, Bedke J, Morgia G, Nikolaou K, Stenzl A, Kruck S.

Clin Genitourin Cancer. 2018 Aug;16(4):e953-e960. doi: 10.1016/j.clgc.2018.03.013. Epub 2018 Apr 3.

PMID: 29685613

92.

Re: Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-resistant Prostate Cancer.

Stenzl A.

Eur Urol. 2020 Jan;77(1):131-132. doi: 10.1016/j.eururo.2019.07.025. Epub 2019 Jul 24.

PMID: 31350066No abstract available.

93.

IMA901: a peptide vaccine in renal cell carcinoma.

Bedke J, Stenzl A.

Expert Opin Investig Drugs. 2013 Oct;22(10):1329-36. doi: 10.1517/13543784.2013.822066. Epub 2013 Jul 31.

PMID: 23899354Review.

94.

Suture causing urethral meatus stricture: A novel animal model of partial bladder outlet obstruction.

Chen L, Yang Y, Yang J, He P, Amend B, Stenzl A, Hu J, Zhang Y, Wang Z.

Neurourol Urodyn. 2018 Sep;37(7):2088-2096. doi: 10.1002/nau.23427. Epub 2018 Jun 28.

PMID: 29953650

95.

Cell-based therapy for the deficient urinary sphincter.

Hart ML, Neumayer KM, Vaegler M, Daum L, Amend B, Sievert KD, Di Giovanni S, Kraushaar U, Guenther E, Stenzl A, Aicher WK.

Curr Urol Rep. 2013 Oct;14(5):476-87. doi: 10.1007/s11934-013-0352-7.

PMID: 23824516Review.

96.

Prostate cancer detection in patients with prior negative biopsy undergoing cognitive-, robotic- or in-bore MRI target biopsy.

Kaufmann S, Russo GI, Bamberg F, Löwe L, Morgia G, Nikolaou K, Stenzl A, Kruck S, Bedke J.

World J Urol. 2018 May;36(5):761-768. doi: 10.1007/s00345-018-2189-7. Epub 2018 Jan 27.

PMID: 29380130

97.

Metabolic and Lipidomic Reprogramming in Renal Cell Carcinoma Subtypes Reflects Regions of Tumor Origin.

Schaeffeler E, Büttner F, Reustle A, Klumpp V, Winter S, Rausch S, Fisel P, Hennenlotter J, Kruck S, Stenzl A, Wahrheit J, Sonntag D, Scharpf M, Fend F, Agaimy A, Hartmann A, Bedke J, Schwab M.

Eur Urol Focus. 2019 Jul;5(4):608-618. doi: 10.1016/j.euf.2018.01.016. Epub 2018 Feb 13.

PMID: 29452772

98.

Total proximal ureter substitution using buccal mucosa.

Fahmy O, Schubert T, Khairul-Asri MG, Stenzl A, Gakis G.

Int J Urol. 2017 Apr;24(4):320-323. doi: 10.1111/iju.13307. Epub 2017 Feb 16.

PMID: 28208217

99.

Bladder cancer: work in progress.

Stenzl A.

Curr Opin Urol. 2009 Sep;19(5):486-7. doi: 10.1097/MOU.0b013e32832f0635.

PMID: 19652558No abstract available.

100.

Isolated, disseminated and circulating tumour cells in prostate cancer.

Schilling D, Todenhöfer T, Hennenlotter J, Schwentner C, Fehm T, Stenzl A.

Nat Rev Urol. 2012 Aug;9(8):448-63. doi: 10.1038/nrurol.2012.136. Epub 2012 Jul 10.

PMID: 22777287Review.

101.

Integrative -omics and HLA-ligandomics analysis to identify novel drug targets for ccRCC immunotherapy.

Reustle A, Di Marco M, Meyerhoff C, Nelde A, Walz JS, Winter S, Kandabarau S, Büttner F, Haag M, Backert L, Kowalewski DJ, Rausch S, Hennenlotter J, Stühler V, Scharpf M, Fend F, Stenzl A, Rammensee HG, Bedke J, Stevanović S, Schwab M, Schaeffeler E.

Genome Med. 2020 Mar 30;12(1):32. doi: 10.1186/s13073-020-00731-8.

PMID: 32228647 Free PMC article.

102.

Stem cell therapy for voiding and erectile dysfunction.

Vaegler M, Lenis AT, Daum L, Amend B, Stenzl A, Toomey P, Renninger M, Damaser MS, Sievert KD.

Nat Rev Urol. 2012 Aug;9(8):435-47. doi: 10.1038/nrurol.2012.111. Epub 2012 Jun 19.

PMID: 22710667Free PMC article.Review.

103.

Immunotherapeutic strategies for the treatment of renal cell carcinoma: where are we now?

Bedke J, Stenzl A.

Expert Rev Anticancer Ther. 2013 Dec;13(12):1399-408. doi: 10.1586/14737140.2013.856761. Epub 2013 Nov 11.

PMID: 24215158Review.

104.

Critical Review of Outcomes from Radical Cystectomy: Can Complications from Radical Cystectomy Be Reduced by Surgical Volume and Robotic Surgery?

Moschini M, Simone G, Stenzl A, Gill IS, Catto J.

Eur Urol Focus. 2016 Apr;2(1):19-29. doi: 10.1016/j.euf.2016.03.001. Epub 2016 Mar 17.

PMID: 28723446Review.

105.

Cystectomy in women.

Schilling D, Horstmann M, Nagele U, Sievert KD, Stenzl A.

BJU Int. 2008 Nov;102(9 Pt B):1289-95. doi: 10.1111/j.1464-410X.2008.07972.x.

PMID: 19035894

106.

Role of multiparametric magnetic resonance imaging for patients under active surveillance for prostate cancer: a systematic review with diagnostic meta-analysis.

Cantiello F, Russo GI, Kaufmann S, Cacciamani G, Crocerossa F, Ferro M, De Cobelli O, Artibani W, Cimino S, Morgia G, Damiano R, Nikolaou K, Kröger N, Stenzl A, Bedke J, Kruck S.

Prostate Cancer Prostatic Dis. 2019 May;22(2):206-220. doi: 10.1038/s41391-018-0113-2. Epub 2018 Nov 28.

PMID: 30487646

107.

Clinical utility of the S3-score for molecular prediction of outcome in non-metastatic and metastatic clear cell renal cell carcinoma.

Büttner F, Winter S, Rausch S, Hennenlotter J, Kruck S, Stenzl A, Scharpf M, Fend F, Agaimy A, Hartmann A, Bedke J, Schwab M, Schaeffeler E.

BMC Med. 2018 Jul 5;16(1):108. doi: 10.1186/s12916-018-1088-5.

PMID: 29973214 Free PMC article.

108.

Can contrast-enhanced ultrasound and acoustic radiation force impulse imaging characterize CT-indeterminate renal masses? A prospective evaluation with histological confirmation.

Thaiss WM, Bedke J, Kruck S, Spira D, Stenzl A, Nikolaou K, Horger M, Kaufmann S.

World J Urol. 2019 Jul;37(7):1339-1346. doi: 10.1007/s00345-018-2520-3. Epub 2018 Oct 15.

PMID: 30324296

109.

Regeneration of degenerated urinary sphincter muscles: improved stem cell-based therapies and novel imaging technologies.

Amend B, Vaegler M, Fuchs K, Mannheim JG, Will S, Kramer U, Hart ML, Feitz W, Chapple C, Stenzl A, Aicher WK.

Cell Transplant. 2015;24(11):2171-83. doi: 10.3727/096368915X686229. Epub 2015 Jan 20.

PMID: 25608017Review.

110.

Contemporary role of salvage lymphadenectomy in patients with recurrence following radical prostatectomy.

Abdollah F, Briganti A, Montorsi F, Stenzl A, Stief C, Tombal B, Van Poppel H, Touijer K.

Eur Urol. 2015 May;67(5):839-49. doi: 10.1016/j.eururo.2014.03.019. Epub 2014 Mar 26.

PMID: 24698524Review.

111.

Metabolic syndrome is not associated with greater evidences of proliferative inflammatory atrophy and inflammation in patients with suspected prostate cancer.

Russo GI, Cimino S, Giranio G, Regis F, Favilla V, Privitera S, Motta F, Caltabiano R, Stenzl A, Todenhöfer T, Morgia G.

Urol Oncol. 2018 May;36(5):240.e21-240.e26. doi: 10.1016/j.urolonc.2018.01.012. Epub 2018 Feb 9.

PMID: 29429896

112.

Best practices in robot-assisted radical cystectomy and urinary reconstruction: recommendations of the Pasadena Consensus Panel.

Wilson TG, Guru K, Rosen RC, Wiklund P, Annerstedt M, Bochner BH, Chan KG, Montorsi F, Mottrie A, Murphy D, Novara G, Peabody JO, Palou Redorta J, Skinner EC, Thalmann G, Stenzl A, Yuh B, Catto J; Pasadena Consensus Panel.

Eur Urol. 2015 Mar;67(3):363-75. doi: 10.1016/j.eururo.2014.12.009. Epub 2015 Jan 9.

PMID: 25582930Review.

113.

mTOR and mTOR phosphorylation status in primary and metastatic renal cell carcinoma tissue: differential expression and clinical relevance.

Rausch S, Schollenberger D, Hennenlotter J, Stühler V, Kruck S, Stenzl A, Bedke J.

J Cancer Res Clin Oncol. 2019 Jan;145(1):153-163. doi: 10.1007/s00432-018-2775-5. Epub 2018 Oct 27.

PMID: 30368665

114.

The latissimus dorsi detrusor myoplasty for functional treatment of bladder acontractility.

Ninkovic M, Stenzl A, Gakis G, Ninkovic M, Voigt S, Dornseifer U.

Clin Plast Surg. 2012 Oct;39(4):507-12. doi: 10.1016/j.cps.2012.07.017.

PMID: 23036300Review.

115.

DNA methylation of neural EGFL like 1 (NELL1) is associated with advanced disease and the metastatic state of renal cell cancer patients.

Peters I, Dubrowinskaja N, Hennenlotter J, Antonopoulos WI, Von Klot CAJ, Tezval H, Stenzl A, Kuczyk MA, Serth J.

Oncol Rep. 2018 Dec;40(6):3861-3868. doi: 10.3892/or.2018.6732. Epub 2018 Sep 24.

PMID: 30272321

116.

IMA901 for metastatic renal cell carcinoma in the context of new approaches to immunotherapy.

Rausch S, Kruck S, Stenzl A, Bedke J.

Future Oncol. 2014 May;10(6):937-48. doi: 10.2217/fon.14.61.

PMID: 24941980Review.

117.

Performance of Urinary Markers for Detection of Upper Tract Urothelial Carcinoma: Is Upper Tract Urine More Accurate than Urine from the Bladder?

Bier S, Hennenlotter J, Esser M, Mohrhardt S, Rausch S, Schwentner C, Maas M, Deininger S, Walz S, Bedke J, Stenzl A, Todenhöfer T.

Dis Markers. 2018 Jan 30;2018:5823870. doi: 10.1155/2018/5823870. eCollection 2018.

PMID: 29651327 Free PMC article.

118.

Systematic review and cumulative analysis of oncologic and functional outcomes after robot-assisted radical cystectomy.

Yuh B, Wilson T, Bochner B, Chan K, Palou J, Stenzl A, Montorsi F, Thalmann G, Guru K, Catto JW, Wiklund PN, Novara G.

Eur Urol. 2015 Mar;67(3):402-22. doi: 10.1016/j.eururo.2014.12.008. Epub 2015 Jan 2.

PMID: 25560797Review.

119.

Targeted therapy in renal cell carcinoma: moving from molecular agents to specific immunotherapy.

Bedke J, Gouttefangeas C, Singh-Jasuja H, Stevanović S, Behnes CL, Stenzl A.

World J Urol. 2014 Feb;32(1):31-8. doi: 10.1007/s00345-013-1033-3. Epub 2013 Feb 12.

PMID: 23404195Free PMC article.Review.

120.

Prognostic impact of tumor-associated immune cell infiltrates at radical cystectomy for bladder cancer.

Schubert T, Renninger M, Schmid MA, Hassan FN, Sokolakis I, Fahmy O, Hatzichristodoulou G, Stenzl A, Gakis G.

Urol Oncol. 2020 Jan;38(1):4.e7-4.e15. doi: 10.1016/j.urolonc.2019.08.013. Epub 2019 Sep 16.

PMID: 31537484

121.

Can we still afford bladder cancer?

Stenzl A, Hennenlotter J, Schilling D.

Curr Opin Urol. 2008 Sep;18(5):488-92. doi: 10.1097/MOU.0b013e32830b8925.

PMID: 18670272Review.

122.

DNA methylation of sarcosine dehydrogenase (SARDH) loci as a prognosticator for renal cell carcinoma.

Mazdak M, Tezval H, Callauch JC, Dubrowinskaja N, Peters I, Bokemeyer C, Hennenlotter J, Stenzl A, Kuczyk MA, Serth J.

Oncol Rep. 2019 Nov;42(5):2159-2168. doi: 10.3892/or.2019.7305. Epub 2019 Sep 9.

PMID: 31545450

123.

Simultaneous whole-body PET/MRI with integrated multiparametric MRI for primary staging of high-risk prostate cancer.

Kaufmann S, Kruck S, Gatidis S, Hepp T, Thaiss WM, Hennenlotter J, Schwenck J, Scharpf M, Nikolaou K, Stenzl A, Reischl G, la Fougère C, Bedke J.

World J Urol. 2020 Oct;38(10):2513-2521. doi: 10.1007/s00345-019-03066-1. Epub 2020 Jan 6.

PMID: 31907632

124.

Can we rely on lymphovascular invasion for determining the need for adjuvant chemotherapy in organ-confined bladder cancer?

Gakis G, Stenzl A.

BJU Int. 2015 Jul;116(1):3-4. doi: 10.1111/bju.13047.

PMID: 26123071No abstract available.

125.

Disseminated and circulating tumor cells for monitoring chemotherapy in urological tumors.

Kruck S, Gakis G, Stenzl A.

Anticancer Res. 2011 Jun;31(6):2053-7.

PMID: 21737622Review.

126.

Immunologic mechanisms in RCC and allogeneic renal transplant rejection.

Bedke J, Stenzl A.

Nat Rev Urol. 2010 Jun;7(6):339-47. doi: 10.1038/nrurol.2010.59. Epub 2010 May 11.

PMID: 20458329Review.

127.

Towards a Treatment of Stress Urinary Incontinence: Application of Mesenchymal Stromal Cells for Regeneration of the Sphincter Muscle.

Aicher WK, Hart ML, Stallkamp J, Klünder M, Ederer M, Sawodny O, Vaegler M, Amend B, Sievert KD, Stenzl A.

J Clin Med. 2014 Feb 24;3(1):197-215. doi: 10.3390/jcm3010197.

PMID: 26237258Free PMC article.Review.

128.

Latissimus dorsi detrusor myoplasty to restore voiding in patients with an acontractile bladder - fact or fiction?

van Koeveringe G, Rademakers K, Stenzl A.

Curr Urol Rep. 2013 Oct;14(5):426-34. doi: 10.1007/s11934-013-0349-2.

PMID: 23775469Review.

129.

Gender-specific differences in muscle-invasive bladder cancer: the concept of sex steroid sensitivity.

Gakis G, Stenzl A.

World J Urol. 2013 Oct;31(5):1059-64. doi: 10.1007/s00345-013-1037-z. Epub 2013 Feb 9.

PMID: 23397433Review.

130.

Pelvic neuroanatomy and recovery of potency.

Stenzl A.

Eur Urol. 2009 Feb;55(2):284-6. doi: 10.1016/j.eururo.2008.11.003. Epub 2008 Nov 20.

PMID: 19022556No abstract available.

131.

Editorial comment.

Stenzl A.

J Urol. 2009 Oct;182(4):1317; discussion 1317. doi: 10.1016/j.juro.2009.06.153. Epub 2009 Aug 14.

PMID: 19683279No abstract available.

132.

Optimal use and outcomes of orthotopic neobladder reconstruction in men and women.

Todenhöfer T, Stenzl A, Schwentner C.

Curr Opin Urol. 2013 Sep;23(5):479-86. doi: 10.1097/MOU.0b013e328363f6e9.

PMID: 23851385Review.

133.

Salvage lymph node dissection in recurrent prostate cancer patients.

Stenzl A.

Eur Urol. 2011 Nov;60(5):944-5. doi: 10.1016/j.eururo.2011.08.027. Epub 2011 Aug 19.

PMID: 21862206No abstract available.

134.

Clinical and cost effectiveness of hexaminolevulinate-guided blue-light cystoscopy: evidence review and updated expert recommendations.

Witjes JA, Babjuk M, Gontero P, Jacqmin D, Karl A, Kruck S, Mariappan P, Palou Redorta J, Stenzl A, van Velthoven R, Zaak D.

Eur Urol. 2014 Nov;66(5):863-71. doi: 10.1016/j.eururo.2014.06.037. Epub 2014 Jul 4.

PMID: 25001887Review.

135.

Automated Definition of Skeletal Disease Burden in Metastatic Prostate Carcinoma: A 3D Analysis of SPECT/CT Images.

Fiz F, Dittmann H, Campi C, Weissinger M, Sahbai S, Reimold M, Stenzl A, Piana M, Sambuceti G, la Fougère C.

Cancers (Basel). 2019 Jun 21;11(6):869. doi: 10.3390/cancers11060869.

PMID: 31234424 Free PMC article.

136.

A novel waterjet technology for transurethral cystoscopic injection of viable cells in the urethral sphincter complex.

Jäger L, Linzenbold W, Fech A, Enderle M, Abruzzese T, Stenzl A, Aicher WK.

Neurourol Urodyn. 2020 Feb;39(2):594-602. doi: 10.1002/nau.24261. Epub 2019 Dec 24.

PMID: 31873953

137.

Labelling and tracking of human mesenchymal stromal cells in preclinical studies and large animal models of degenerative diseases.

Vaegler M, Maerz JK, Amend B, da Silva LA, Mannheim JG, Fuchs K, Will S, Sievert KD, Stenzl A, Hart ML, Aicher WK.

Curr Stem Cell Res Ther. 2014;9(5):444-50. doi: 10.2174/1574888x09666140521144559.

PMID: 24853377Review.

138.

Secondary hormonal manipulation.

Merseburger AS, Belka C, Behmenburg K, Stenzl A.

Front Radiat Ther Oncol. 2008;41:93-102. doi: 10.1159/000139883.

PMID: 18544990Review.

139.

Words of Wisdom. Re: Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.

Bedke J, Stenzl A.

Eur Urol. 2016 Mar;69(3):538-9. doi: 10.1016/j.eururo.2015.12.025.

PMID: 26867725No abstract available.

140.

Technical solutions to improve the management of non-muscle-invasive transitional cell carcinoma: summary of a European Association of Urology Section for Uro-Technology (ESUT) and Section for Uro-Oncology (ESOU) expert meeting and current and future perspectives.

Bach T, Muschter R, Herrmann TR, Knoll T, Scoffone CM, Laguna MP, Skolarikos A, Rischmann P, Janetschek G, De la Rosette JJ, Nagele U, Malavaud B, Breda A, Palou J, Bachmann A, Frede T, Geavlete P, Liatsikos E, Jichlinski P, Schwaibold HE, Chlosta P, Martov AG, Lapini A, Schmidbauer J, Djavan B, Stenzl A, Brausi M, Rassweiler JJ.

BJU Int. 2015 Jan;115(1):14-23. doi: 10.1111/bju.12664. Epub 2014 Jul 14.

PMID: 25646531Review.

141.

The prognostic value of hematological and systemic inflammatory disorders in invasive bladder cancer.

Gakis G, Todenhöfer T, Stenzl A.

Curr Opin Urol. 2011 Sep;21(5):428-33. doi: 10.1097/MOU.0b013e32834966fa.

PMID: 21730850Review.

142.

Contemporary role of prostate cancer antigen 3 in the management of prostate cancer.

Auprich M, Bjartell A, Chun FK, de la Taille A, Freedland SJ, Haese A, Schalken J, Stenzl A, Tombal B, van der Poel H.

Eur Urol. 2011 Nov;60(5):1045-54. doi: 10.1016/j.eururo.2011.08.003. Epub 2011 Aug 25.

PMID: 21871709Review.

143.

From tissue engineering to regenerative medicine in urology--the potential and the pitfalls.

Feil G, Daum L, Amend B, Maurer S, Renninger M, Vaegler M, Seibold J, Stenzl A, Sievert KD.

Adv Drug Deliv Rev. 2011 Apr 30;63(4-5):375-8. doi: 10.1016/j.addr.2010.12.003. Epub 2010 Dec 15.

PMID: 21167237Review.

144.

Current status of molecular markers for prognostication and outcome in invasive bladder cancer.

Gakis G, Schwentner C, Todenhöfer T, Stenzl A.

BJU Int. 2012 Jul;110(2):233-7. doi: 10.1111/j.1464-410X.2011.10839.x. Epub 2012 Jan 11.

PMID: 22233187Review.

145.

Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines.

Stenzl A, Cowan NC, De Santis M, Kuczyk MA, Merseburger AS, Ribal MJ, Sherif A, Witjes JA; European Association of Urology (EAU).

Eur Urol. 2011 Jun;59(6):1009-18. doi: 10.1016/j.eururo.2011.03.023. Epub 2011 Mar 23.

PMID: 21454009Review.

146.

The prognostic impact of hexaminolevulinate-based bladder tumor resection in patients with primary non-muscle invasive bladder cancer treated with radical cystectomy.

Renninger M, Fahmy O, Schubert T, Schmid MA, Hassan F, Stenzl A, Gakis G.

World J Urol. 2020 Feb;38(2):397-406. doi: 10.1007/s00345-019-02780-0. Epub 2019 Apr 27.

PMID: 31030231

147.

Assessment of concomitant non-oncologic medication in patients with surgically treated renal cell carcinoma: impact on prognosis, cell-cycle progression and proliferation.

Neumann E, Klaiber P, Freitag K, Schwab M, Schaeffeler E, Hennenlotter J, Fend F, Kruck S, Scharpf M, Stenzl A, Bedke J, Rausch S.

J Cancer Res Clin Oncol. 2019 Jul;145(7):1835-1843. doi: 10.1007/s00432-019-02914-2. Epub 2019 Apr 22.

PMID: 31006846

148.

Comment on "Epigenetic activation of the drug transporter OCT2 sensitizes renal cell carcinoma to oxaliplatin".

Winter S, Fisel P, Büttner F, Nies AT, Stenzl A, Bedke J, Schwab M, Schaeffeler E.

Sci Transl Med. 2017 May 24;9(391):eaal2439. doi: 10.1126/scitranslmed.aal2439.

PMID: 28539468No abstract available.

149.

Orthotopic bladder reconstruction in women--what we have learned over the last decade.

Stenzl A, Höltl L.

Crit Rev Oncol Hematol. 2003 Aug;47(2):147-54. doi: 10.1016/s1040-8428(03)00078-7.

PMID: 12900008Review.

150.

The updated EAU guidelines on muscle-invasive and metastatic bladder cancer.

Stenzl A, Cowan NC, De Santis M, Jakse G, Kuczyk MA, Merseburger AS, Ribal MJ, Sherif A, Witjes JA.

Eur Urol. 2009 Apr;55(4):815-25. doi: 10.1016/j.eururo.2009.01.002. Epub 2009 Jan 13.

PMID: 19157687Review.

151.

Chronic Periodontitis Does Not Impact Serum Levels of Prostate-specific Antigen.

Kruck S, Hennenlotter J, Amend B, Geiger M, Filipova E, Neumann T, Stühler V, Schubert T, Todenhöfer T, Rausch S, Huettig F, Stenzl A, Bedke J.

Anticancer Res. 2017 Jun;37(6):3163-3167. doi: 10.21873/anticanres.11675.

PMID: 28551659

152.

Rho GDP dissociation inhibitor-β in renal cell carcinoma.

von Klot CA, Dubrowinskaja N, Peters I, Hennenlotter J, Merseburger AS, Stenzl A, Kuczyk MA, Serth J.

Oncol Lett. 2017 Dec;14(6):8190-8196. doi: 10.3892/ol.2017.7233. Epub 2017 Oct 20.

PMID: 29250194 Free PMC article.

153.

Endoscopic inguinofemoral lymphadenectomy--extended follow-up.

Schwentner C, Todenhöfer T, Seibold J, Alloussi SH, Mischinger J, Aufderklamm S, Stenzl A, Gakis G.

J Endourol. 2013 Apr;27(4):497-503. doi: 10.1089/end.2012.0489. Epub 2012 Dec 26.

PMID: 23067251

154.

Laparoscopic versus Open Partial Nephrectomy: Comparison of Overall and Subgroup Outcomes.

Abdelhafez M, Bastian A, Rausch S, Stenzl A, Bedke J, Kruck S.

Anticancer Res. 2017 Jan;37(1):261-265. doi: 10.21873/anticanres.11316.

PMID: 28011501Clinical Trial.

155.

Role of 11C-choline positron emission tomography in prostate cancer recurrence--potential for delayed cure or just resetting the clock of the disease?

Gakis G, Stenzl A.

J Urol. 2015 Jan;193(1):12-3. doi: 10.1016/j.juro.2014.10.057. Epub 2014 Oct 17.

PMID: 25444969No abstract available.

156.

Androgen receptor overexpression in prostate cancer in type 2 diabetes.

Lutz SZ, Hennenlotter J, Scharpf MO, Sailer C, Fritsche L, Schmid V, Kantartzis K, Wagner R, Lehmann R, Berti L, Peter A, Staiger H, Fritsche A, Fend F, Todenhöfer T, Stenzl A, Häring HU, Heni M.

Mol Metab. 2018 Feb;8:158-166. doi: 10.1016/j.molmet.2017.11.013. Epub 2017 Dec 5.

PMID: 29249638 Free PMC article.

157.

Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data.

Burger M, Grossman HB, Droller M, Schmidbauer J, Hermann G, Drăgoescu O, Ray E, Fradet Y, Karl A, Burgués JP, Witjes JA, Stenzl A, Jichlinski P, Jocham D.

Eur Urol. 2013 Nov;64(5):846-54. doi: 10.1016/j.eururo.2013.03.059. Epub 2013 Apr 8.

PMID: 23602406Review.

158.

The role of radical prostatectomy and lymph node dissection in lymph node-positive prostate cancer: a systematic review of the literature.

Gakis G, Boorjian SA, Briganti A, Joniau S, Karazanashvili G, Karnes RJ, Mattei A, Shariat SF, Stenzl A, Wirth M, Stief CG.

Eur Urol. 2014 Aug;66(2):191-9. doi: 10.1016/j.eururo.2013.05.033. Epub 2013 May 22.

PMID: 23735200Review.

159.

Hexyl aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: a critical review of the current literature.

Rink M, Babjuk M, Catto JW, Jichlinski P, Shariat SF, Stenzl A, Stepp H, Zaak D, Witjes JA.

Eur Urol. 2013 Oct;64(4):624-38. doi: 10.1016/j.eururo.2013.07.007. Epub 2013 Jul 19.

PMID: 23906669Review.

160.

ICUD-EAU International Consultation on Bladder Cancer 2012: Radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder.

Gakis G, Efstathiou J, Lerner SP, Cookson MS, Keegan KA, Guru KA, Shipley WU, Heidenreich A, Schoenberg MP, Sagaloswky AI, Soloway MS, Stenzl A; International Consultation on Urologic Disease-European Association of Urology Consultation on Bladder Cancer 2012.

Eur Urol. 2013 Jan;63(1):45-57. doi: 10.1016/j.eururo.2012.08.009. Epub 2012 Aug 14.

PMID: 22917985Review.

161.

Is there an anti-androgen withdrawal syndrome for enzalutamide?

von Klot CA, Kramer MW, Böker A, Herrmann TR, Peters I, Kuczyk MA, Ligges U, Gschwend JE, Retz M, Schmid SC, Stenzl A, Schwentner C, Todenhöfer T, Stöckle M, Ohlmann CH, Azone I, Mager R, Bartsch G, Haferkamp A, Heidenreich A, Piper C, Merseburger AS.

World J Urol. 2014 Oct;32(5):1171-6. doi: 10.1007/s00345-014-1288-3. Epub 2014 Apr 2.

PMID: 24691670

162.

Adjuvant radiotherapy for patients with locally advanced prostate cancer--a new standard?

Ganswindt U, Stenzl A, Bamberg M, Belka C.

Eur Urol. 2008 Sep;54(3):528-42. doi: 10.1016/j.eururo.2008.06.059. Epub 2008 Jun 23.

PMID: 18602742Review.

163.

Oncologic Impact of Renal Tissue Adjacent to Renal Cell Carcinoma.

Aufderklamm S, Hennenlotter J, Todenhöfer T, Senghaas N, Scharpf M, Gakis G, Rausch S, Mischinger J, Bier S, Stenzl A, Schwentner C, Bedke J.

Anticancer Res. 2016 Jun;36(6):2865-9.

PMID: 27272798

164.

Bladder hypocontractility--extending the indication for LDDM.

Gakis G, Ninkovic M, Stenzl A.

Nat Rev Urol. 2012 Mar 27;9(4):231. doi: 10.1038/nrurol.2011.27-c1.

PMID: 22450607No abstract available.

165.

Prostate tumor overexpressed 1 expression in invasive urothelial carcinoma.

Rausch S, Hennenlotter J, Scharpf M, Teepe K, Kühs U, Aufderklamm S, Bier S, Mischinger J, Gakis G, Stenzl A, Schwentner C, Todenhöfer T.

J Cancer Res Clin Oncol. 2016 May;142(5):937-47. doi: 10.1007/s00432-015-2107-y. Epub 2016 Jan 8.

PMID: 26746655

166.

The thermoexpandable nitinol stent: a long-term alternative in patients without nephropathy or malignancy.

Bier S, Amend B, Wagner E, Rausch S, Mischinger J, Neumann E, Stühler V, Hennenlotter J, Todenhoefer T, Stenzl A, Bedke J, Kruck S.

Scand J Urol. 2017 Oct;51(5):388-391. doi: 10.1080/21681805.2017.1331262. Epub 2017 Jun 23.

PMID: 28644054

167.

Minimal Invasive Cystometry and Intra-Abdominal Pressure Assessments in Rodents: A Novel Animal Study.

Yang Y, Yang J, Chen L, Hu J, Xing S, Amend B, Stenzl A, Wei X, Hu H.

Med Sci Monit. 2017 May 24;23:2500-2507. doi: 10.12659/msm.904760.

PMID: 28538709 Free PMC article.

168.

Urothelial carcinoma of the bladder and the upper tract: disparate twins.

Green DA, Rink M, Xylinas E, Matin SF, Stenzl A, Roupret M, Karakiewicz PI, Scherr DS, Shariat SF.

J Urol. 2013 Apr;189(4):1214-21. doi: 10.1016/j.juro.2012.05.079. Epub 2012 Sep 27.

PMID: 23023150Review.

169.

Ex vivo γH2AX radiation sensitivity assay in prostate cancer: Inter-patient and intra-patient heterogeneity.

De-Colle C, Yaromina A, Hennenlotter J, Thames H, Mueller AC, Neumann T, Stenzl A, Scharpf M, Fend F, Ricardi U, Baumann M, Zips D, Menegakis A.

Radiother Oncol. 2017 Sep;124(3):386-394. doi: 10.1016/j.radonc.2017.08.020. Epub 2017 Sep 14.

PMID: 28919005

170.

Tissue engineering for the lower urinary tract: a review of a state of the art approach.

Sievert KD, Amend B, Stenzl A.

Eur Urol. 2007 Dec;52(6):1580-9. doi: 10.1016/j.eururo.2007.08.051. Epub 2007 Sep 4.

PMID: 17889986Review.

171.

Oncological Outcomes of Patients with Concomitant Bladder and Urethral Carcinoma.

Gakis G, Efstathiou JA, Daneshmand S, Keegan KA, Clayman RH, Hrbacek J, Ali-El-Dein B, Zaid HB, Schubert T, Mischinger J, Todenhöfer T, Galland S, Olugbade K Jr, Rink M, Fritsche HM, Burger M, Chang SS, Babjuk M, Thalmann GN, Stenzl A, Morgan TM.

Urol Int. 2016;97(2):134-41. doi: 10.1159/000448335. Epub 2016 Jul 28.

PMID: 27462702

172.

Establishing and monitoring of urethral sphincter deficiency in a large animal model.

Kelp A, Albrecht A, Amend B, Klünder M, Rapp P, Sawodny O, Stenzl A, Aicher WK.

World J Urol. 2017 Dec;35(12):1977-1986. doi: 10.1007/s00345-017-2088-3. Epub 2017 Sep 22.

PMID: 28940030

173.

Role of Multiparametric Magnetic Resonance Imaging in Predicting Pathologic Outcomes in Prostate Cancer.

Harland N, Stenzl A, Todenhöfer T.

World J Mens Health. 2020 Jun 24. doi: 10.5534/wjmh.200030. Online ahead of print.

PMID: 32648376Review.

174.

Eliminating pulse-induced artifacts in Urethral Pressure data.

Klunder M, Feuer R, Amend B, Kelp A, Stenzl A, Sievert KD, Sawodny O, Ederer M.

Annu Int Conf IEEE Eng Med Biol Soc. 2015 Aug;2015:2779-83. doi: 10.1109/EMBC.2015.7318968.

PMID: 26736868

175.

Photodynamic diagnosis in non-muscle-invasive bladder cancer: a systematic review and cumulative analysis of prospective studies.

Kausch I, Sommerauer M, Montorsi F, Stenzl A, Jacqmin D, Jichlinski P, Jocham D, Ziegler A, Vonthein R.

Eur Urol. 2010 Apr;57(4):595-606. doi: 10.1016/j.eururo.2009.11.041. Epub 2009 Dec 2.

PMID: 20004052Review.

176.

Corrigendum re: "Early Recurrence Patterns Following Totally Intracorporeal Robot-assisted Radical Cystectomy: Results from the EAU Robotic Urology Section (ERUS) Scientific Working Group" [Eur Urol 2017;71:723-6].

Collins JW, Hosseini A, Adding C, Nyberg T, Koupparis A, Rowe E, Perry M, Issa R, Schumacher MC, Wijburg C, Canda AE, Balbay M, Decaestecker K, Schwentner C, Stenzl A, Edeling S, Pokupić S, D'Hondt F, Mottrie A, Wiklund PN.

Eur Urol. 2017 Sep;72(3):e80. doi: 10.1016/j.eururo.2017.04.014. Epub 2017 Apr 27.

PMID: 28457662No abstract available.

177.

Factors influencing false-positive results for nuclear matrix protein 22.

Behrens T, Stenzl A, Brüning T.

Eur Urol. 2014 Nov;66(5):970-2. doi: 10.1016/j.eururo.2014.06.014. Epub 2014 Jun 26.

PMID: 24976592No abstract available.

178.

Radical cystectomy with orthotopic neobladder for invasive bladder cancer: a critical analysis of long-term oncological, functional, and quality of life results.

Nagele U, Anastasiadis AG, Stenzl A, Kuczyk M.

World J Urol. 2012 Dec;30(6):725-32. doi: 10.1007/s00345-011-0649-4. Epub 2011 Feb 5.

PMID: 21298273Review.

179.

Signal processing in urodynamics: towards high definition urethral pressure profilometry.

Klünder M, Sawodny O, Amend B, Ederer M, Kelp A, Sievert KD, Stenzl A, Feuer R.

Biomed Eng Online. 2016 Mar 22;15:31. doi: 10.1186/s12938-016-0145-6.

PMID: 27000558 Free PMC article.

180.

Bladder cancer: chemoprevention, complementary approaches and budgetary considerations.

Grossman HB, Stenzl A, Moyad MA, Droller MJ.

Scand J Urol Nephrol Suppl. 2008 Sep;(218):213-33. doi: 10.1080/03008880802284258.

PMID: 18815935Review.

181.

New technique for needle-less implantation of eukaryotic cells.

Arenas da Silva LF, Schober L, Sloff M, Traube A, Hart ML, Feitz WF, Stenzl A.

Cytotherapy. 2015 Nov;17(11):1655-61. doi: 10.1016/j.jcyt.2015.07.017. Epub 2015 Sep 3.

PMID: 26344464

182.

Prognostic Significance of Incidental Prostate Cancer at Radical Cystoprostatectomy for Bladder Cancer.

Gakis G, Rink M, Fritsche HM, Graefen M, Schubert T, Hassan F, Chun FK, Brummeisl W, Fisch M, Burger M, Stenzl A, Renninger M.

Urol Int. 2016;97(1):42-8. doi: 10.1159/000443239. Epub 2016 Jan 9.

PMID: 26744841

183.

C-reactive protein in bladder cancer: where do we stand?

Gakis G, Stenzl A.

Nat Rev Urol. 2013 Mar;10(3):182. doi: 10.1038/nrurol.2011.145-c1. Epub 2013 Feb 5.

PMID: 23381597No abstract available.

184.

A vaccine in renal cell carcinoma: are we nearing reality?

Bedke J, Gouttefangeas C, Kruck S, Stenzl A.

Expert Rev Anticancer Ther. 2012 Dec;12(12):1503-5. doi: 10.1586/era.12.139.

PMID: 23253216No abstract available.

185.

Circulating fibronectin controls tumor growth.

von Au A, Vasel M, Kraft S, Sens C, Hackl N, Marx A, Stroebel P, Hennenlotter J, Todenhöfer T, Stenzl A, Schott S, Sinn HP, Wetterwald A, Bermejo JL, Cecchini MG, Nakchbandi IA.

Neoplasia. 2013 Aug;15(8):925-38. doi: 10.1593/neo.13762.

PMID: 23908593 Free PMC article.

186.

The Value and Evaluability of the PCA3 Urine Assay in Prostate Carcinoma is Independent of the Tumor Localization.

Neumann E, Hennenlotter J, Todenhöfer T, Scharpf M, Neumann T, Schilling D, Stenzl A, Bedke J.

Adv Ther. 2017 Apr;34(4):966-974. doi: 10.1007/s12325-017-0510-2. Epub 2017 Mar 13.

PMID: 28290096

187.

Is The Cancer Genome Atlas (TCGA) bladder cancer cohort representative of invasive bladder cancer?

Seiler R, Black PC, Thalmann G, Stenzl A, Todenhöfer T.

Urol Oncol. 2017 Jul;35(7):458.e1-458.e7. doi: 10.1016/j.urolonc.2017.01.024. Epub 2017 Mar 11.

PMID: 28291637

188.

Molecular Signatures of Primary Human Spermatogonial Progenitors and Its Neighboring Peritubular Stromal Compartment.

Harichandan A, Sivasubramaniyan K, Hennenlotter J, Poths S, Bedke J, Kruck S, Stenzl A, Bühring HJ.

Stem Cells Dev. 2017 Feb 15;26(4):263-273. doi: 10.1089/scd.2016.0042. Epub 2016 Dec 16.

PMID: 27821019

189.

Systemic anti-CTLA-4 and intravesical Bacille-Calmette-Guerin therapy in non-muscle invasive bladder cancer: Is there a rationale of synergism?

Fahmy O, Khairul-Asri MG, Stenzl A, Gakis G.

Med Hypotheses. 2016 Jul;92:57-8. doi: 10.1016/j.mehy.2016.04.037. Epub 2016 Apr 23.

PMID: 27241256

190.

Differential expression and clinical relevance of MUC1 in renal cell carcinoma metastasis.

Rausch S, Beermann J, Scharpf M, Hennenlotter J, Fend F, Stenzl A, Schollenberger D, Bedke J, Kruck S.

World J Urol. 2016 Dec;34(12):1635-1641. doi: 10.1007/s00345-016-1804-8. Epub 2016 Mar 19.

PMID: 26995391

191.

Prediction of Postoperative Risks in Laparoscopic Partial Nephrectomy Using RENAL, Mayo Adhesive Probability and Renal Pelvic Score.

Bier S, Aufderklamm S, Todenhöfer T, Kruck S, Schuster K, Rausch S, Othman A, Notohamiprodjo M, Nikolaou K, Schwentner C, Stenzl A, Bier G, Bedke J.

Anticancer Res. 2017 Mar;37(3):1369-1373. doi: 10.21873/anticanres.11457.

PMID: 28314305

192.

Urinary biomarkers in bladder cancer: A review of the current landscape and future directions.

Ng K, Stenzl A, Sharma A, Vasdev N.

Urol Oncol. 2020 Sep 9:S1078-1439(20)30368-9. doi: 10.1016/j.urolonc.2020.08.016. Online ahead of print.

PMID: 32919875Review.

193.

Radical cystectomy with orthotopic neobladder for invasive bladder cancer: a critical analysis of long term oncological, functional and quality of life results.

Stenzl A, Sherif H, Kuczyk M.

Int Braz J Urol. 2010 Sep-Oct;36(5):537-47. doi: 10.1590/s1677-55382010000500003.

PMID: 21044370Review.

194.

The "I-Pouch": Results of a new ileal neobladder technique.

Gakis G, Abdelhafez MF, Stenzl A.

Scand J Urol. 2015;49(5):400-6. doi: 10.3109/21681805.2015.1040451. Epub 2015 Apr 28.

PMID: 25921359

195.

Isolation of adult human spermatogonial progenitors using novel markers.

Harichandan A, Sivasubramaniyan K, Hennenlotter J, Schwentner C, Stenzl A, Bühring HJ.

J Mol Cell Biol. 2013 Oct;5(5):351-3. doi: 10.1093/jmcb/mjt029. Epub 2013 Aug 8.

PMID: 23929715No abstract available.

196.

The prognostic effect of salvage surgery and radiotherapy in patients with recurrent primary urethral carcinoma.

Gakis G, Schubert T, Morgan TM, Daneshmand S, Keegan KA, Mischinger J, Clayman RH, Brisuda A, Ali-El-Dein B, Galland S, Gregg J, Balci M, Olugbade K Jr, Rink M, Fritsche HM, Burger M, Babjuk M, Stenzl A, Thalmann GN, Kübler H, Efstathiou JA.

Urol Oncol. 2018 Jan;36(1):10.e7-10.e14. doi: 10.1016/j.urolonc.2017.09.012. Epub 2017 Oct 18.

PMID: 29055518

197.

Impact of variant microscopic interpretation of the uCyt+ immunocytological urine test for the detection of bladder cancer.

Deininger S, Todenhöfer T, Hennenlotter J, Gerber V, Schwarz J, Bedke J, Schwentner C, Stenzl A, Rausch S.

Diagn Cytopathol. 2018 Feb;46(2):111-116. doi: 10.1002/dc.23857. Epub 2017 Nov 8.

PMID: 29115014

198.

Are we ready for a home-grown urinary sphincter?

Stenzl A, Sievert KD.

Eur Urol. 2007 Dec;52(6):1574-5. doi: 10.1016/j.eururo.2007.06.025. Epub 2007 Jun 26.

PMID: 17606320No abstract available.

199.

Assessment of a new point-of-care system for detection of prostate specific antigen.

Rausch S, Hennenlotter J, Wiesenreiter J, Hohneder A, Heinkele J, Schwentner C, Stenzl A, Todenhöfer T.

BMC Urol. 2016 Jan 19;16:4. doi: 10.1186/s12894-016-0119-9.

PMID: 26785797 Free PMC article.

200.

Surgical reconstruction for male-to-female sex reassignment.

Amend B, Seibold J, Toomey P, Stenzl A, Sievert KD.

Eur Urol. 2013 Jul;64(1):141-9. doi: 10.1016/j.eururo.2012.12.030. Epub 2013 Jan 5.

PMID: 23375962

 

Akademische Ausbildung mit Abschluss

  • Medical School (1973 – 1980), Karl-Franzens-Universität, Graz

Wissenschaftliche Abschlüsse

  • 1980 Promotion zum Doctor medicinae universalis (M.D.)
  • 2017 Honorarium Doctor Dr. h.c. (Bukarest)

Beruflicher Werdegang nach Studienabschluss

  • seit 2002 Ärztlicher Direktor der Klinik für Urologie, Eberhard-Karls-Universität Tübingen
  • 1992 – 2002 Oberarzt bzw. GF OA und Stellvertreter des Vorstandes an der urologischen Universitätsklinik, Innsbruck
    (Vorstand: Univ. Prof. Dr. G. Bartsch), Leiter der urologisch-onkologischen Ambulanz
  • 1990 – 1992 Oberarzt an der urologischen Universitätsklinik, Inselspital, Bern, Schweiz (Vorstand: Prof. E.J. Zingg)
  • 1989 – 1990 Department für Urologie der Chirurgischen Universitäsklinik am LKH Graz (Leiter: Univ. Prof. Dr. G.
    Hubmer)
  • seit 1989 heute, als Facharzt für Urologie in die Ärzteliste der Österreichischen Ärztekammer eingetragen
  • 1988 – 1989 Urologic Oncology Fellow, Division of Urology, Department of Surgery (Vorstand Prof. J.B. deKernion),
    University of California, Los Angeles, USA
  • 1987 – 1988 Resident (Fellow in General Urology) Division of Urology, University of California, Los Angeles, USA
    (Vorstand Prof. J.B. deKernion)
  • 1984 – 1987 Universitätsassistent am Department für Urologie (Leiter: Univ. Prof. Dr. G. Hubmer) der Chirurgischen
    Universitätsklinik in Ausbildung zum Facharzt für Urologie
  • 1983 – 1984 Rotation durch die Departments für Allgemein-, Herz-, Gefäß-, Thorax-, Unfall-, Plastische und
    Experimentelle Chirurgie
  • 1983 – 1987 Universitätsassistent an der Chirurgischen Universitätsklinik am LKH Graz, Vorstand: Univ. Prof. Dr.
    J. Kraft-Kinz
  • 1981 – 1983 Universitätsassistent am Pathologisch-Anatomischen Institut der Karl-Franzens Universität Graz,
    Vorstand: Univ. Prof. Dr. H. Denk
  • 1981 II. Medizinische Abteilung des Landeskrankenhauses Klagenfurt, Univ. Prof. Dr. Sterz: Turnusarzt
  • 1980 I. Medizinische Abteilung des Landeskrankenhauses Klagenfurt, Prim. Moritz: Turnusarzt (davon 4 Monate auf
    der nephrologischen Abteilung)

Auszeichnungen

  • 2011 Jackson Hole Award of Excellence, USA

Review-Tätigkeiten für

  • Journal of Urology
  • European Urology
  • Current Opinion in Urology

Sonstiges

  • seit 2019 Adjunct Secretary General responsible for Science
  • 2018 – 2021 2. Vize-Präsident, anschließend Kongresspräsident der Deutsche Gesellschaft für Urologie
  • seit 2013 Executive Board SFB 685 – Immuntherapie: Von den molekularen Grundlagen zur klinischen Anwendung
  • 2013 – 2018 Vorsitzender des Reinhard-Nagel Stiftungsrates
  • 2012 – 2019 Direktor des Scientific Congress Office der Europäischen Gesellschaft für Urologie
  • 2012 – 2014 Mitglied des Nutzerbeirats, Zentrum für klinische Forschung des Universitätsklinikums und der Medizinischen Fakultät Tübingen (ZKS)
  • seit 2012 International Advisory Board des Journals “Scandinavian Journal of Urology and Nephrology”
  • seit 2009 Direktorium des Interuniversitären Zentrums für Medizinische Technologie Stuttgart-Tübingen (IZST)
  • seit 2008 Mitglied des Scientific Review Boards des Südwestdeutschen Tumorzentrums- Comprehensive Cancer
    Center, Tübingen
  • seit 2008 International Member der American Association of Genitourinary Surgeons
  • seit 2008 Honorary Member „The New York Section of the American Urological Association Inc.“
  • seit 2005 Vorstand Südwestdeutsches Tumorzentrum Tübingen
To the top of the page